Chemkart India FY26: Profit Tumbles 61% Amidst Revenue Growth and Customs Litigation

Chemkart India Ltd reported consolidated revenue from operations of ₹215.49 crore for the financial year ended March 31, 2026. However, its profit after tax for the same period saw a sharp decline to ₹9.51 crore.

Reader Takeaway: Revenue grew on volume; profit plunges amid custom duty payment risk.

What just happened (today’s filing)

The Board of Directors of Chemkart India Ltd met on May 18, 2026, to approve the audited financial results for FY26.

The company's statutory auditors, M/s. Bagaria & Co. LLP, provided an unmodified opinion on the financials.

Consolidated revenue from operations for FY26 stood at ₹21,549.41 lakh (₹215.49 crore), an increase from ₹20,545.63 lakh (₹205.45 crore) in FY25.

However, consolidated Profit After Tax (PAT) significantly decreased to ₹950.57 lakh (₹9.51 crore) in FY26, down from ₹2,451.90 lakh (₹24.51 crore) in the previous fiscal year.

Profit Before Tax (PBT) also saw a sharp drop to ₹1,308.05 lakh (₹13.08 crore) from ₹3,247.52 lakh (₹32.47 crore) in FY25.

Earnings Per Share (EPS) basic fell to ₹7.86 in FY26 from ₹26.06 in FY25.

Regarding IPO proceeds, ₹4.61 crore was utilised for the manufacturing facility, ₹20 crore for borrowings repayment, and ₹28.00 crore remained unutilised, invested in liquid funds as of March 31, 2026.

The company paid ₹1,474.26 lakh (₹14.74 crore) concerning pending customs litigation, which it assesses as recoverable.

Why this matters

The substantial drop in profitability despite revenue growth raises concerns about cost management and margin pressures within Chemkart India's operations.

The payment for customs litigation and the assessment of its recoverability introduce a note of financial uncertainty.

Appointments of M/s. Vinay Bhushan & Associates as Internal Auditors for FY2027 and M/s. Nirmal Tiwari & Associates as Secretarial Auditors for FY2026 reinforce the company's compliance framework.

The backstory (grounded)

Chemkart India Ltd, a manufacturer of specialty chemicals and pharmaceutical intermediates, raised approximately ₹64.48 crore via its IPO in March 2024. Funds were earmarked for capital expenditure, working capital, and general corporate purposes.

The company has faced ongoing litigation with Customs Authorities, leading to a significant payment of ₹14.74 crore as of March 31, 2026.

What changes now

Shareholders now have clear audited financial figures for FY26, showing a challenging profit performance.

The appointment of new internal and secretarial auditors signals the ongoing strengthening of corporate governance procedures.

Key financial risk factors are highlighted, particularly the recoverability of the custom duty payment.

Risks to watch

Customs Litigation Outcome: Uncertainty surrounds the recoverability of the ₹14.74 crore paid towards pending customs duty litigation. The company's assessment of recoverability is a critical factor to monitor.

Margin Compression: The sharp decline in PAT (61%) and PBT (60%) on a relatively modest revenue increase (5%) indicates significant operational cost pressures or margin erosion that requires deeper investigation.

Peer comparison

Chemkart India's peers in the specialty chemical sector, such as Neogen Chemicals Ltd and Tatva Chintan Pharma Chem Ltd, have generally demonstrated more stable profit growth trends in recent fiscal periods.

This stark contrast suggests that Chemkart India might be facing company-specific operational challenges or cost management issues that are impacting its profitability more severely than its comparable listed peers.

Context metrics (time-bound)

(No aggregator data found for this section based on provided input.)

What to track next

Detailed management commentary on the drivers behind the steep profit decline and cost increases.

Updates on the customs litigation, particularly any developments regarding the recoverability of the ₹14.74 crore paid.

The company's operational performance and margin trajectory in the initial quarters of FY27.

Further utilisation of the remaining IPO funds, if any.